NewsAI-assisted

Mankind Pharma Signs Exclusive India Deal with Betta Pharmaceuticals

Mankind Pharma secures exclusive India commercialisation rights for Betta's FDA-approved ALK inhibitor Ensartinib, targeting ALK-positive NSCLC patients.

Vaibhavi M.
By Vaibhavi M.
Subject Matter Expert · Pharma Now
Nov 17, 20262 min read
Mankind Pharma Signs Exclusive India Deal with Betta Pharmaceuticals
AI-assisted reporting
Reviewed by Vaibhavi M., Subject Matter Expert · Pharma Now
50/ 100
Trust score
Needs review

Mankind Pharma's in-licensing of Ensartinib from Betta Pharmaceuticals signals a deliberate shift in how large Indian generics players are approaching oncology, moving from domestic molecule development toward acquiring commercial rights to FDA-approved targeted therapies with established clinical profiles. For market access and regulatory affairs leads, the deal raises immediate questions around import licensing, pricing negotiations under India's drug price control framework, and post-marketing surveillance obligations for a novel ALK inhibitor entering a competitive therapeutic space.

Ensartinib is a second-generation ALK (anaplastic lymphoma kinase) inhibitor indicated for ALK-positive non-small cell lung cancer (NSCLC), a molecularly defined subgroup representing roughly 3–5% of NSCLC diagnoses. The compound received FDA approval and has demonstrated activity in patients with prior crizotinib exposure, positioning it against established agents including alectinib and brigatinib. Mankind's exclusive India rights grant the company sole commercialisation authority in one of the region's fastest-growing oncology markets, where ALK-positive NSCLC diagnosis rates are rising alongside expanded molecular testing infrastructure.

For QA directors and regulatory leads at Mankind, the near-term workload centres on Central Drugs Standard Control Organisation (CDSCO) registration under Rule 122B of the Drugs and Cosmetics Act, which governs new drug approvals for already-approved foreign molecules. Betta's existing FDA dossier provides a substantive technical package, but local bridging data requirements and labelling compliance with Schedule D norms will require coordination between Mankind's regulatory affairs function and Betta's CMC team. Supply chain continuity, specifically, maintaining cold-chain integrity and import batch release timelines, will be an early operational checkpoint.

The broader portfolio read is straightforward: Mankind is constructing an oncology franchise through in-licensing rather than internal R&D, a capital-efficient model that compresses time-to-market but transfers dependency on the originator's manufacturing compliance and batch release schedules. Plant heads managing secondary packaging and distribution for imported finished dosage forms will need to align with 21 CFR Part 211-compliant documentation from Betta's facilities to satisfy CDSCO import requirements.

CDSCO review timelines for new drug applications in the oncology category, and Mankind's ability to secure a viable patient access price point, will determine how quickly Ensartinib reaches prescribers in India's tertiary oncology centres.

Source: Media4Growth via Indian Pharma Post, 15 November 2026.

Read the original release ↗
TopicsNews
Vaibhavi M.
Written by
Vaibhavi M.
Subject Matter Expert · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Loading discussion…

More from Pharma News

All stories →